Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management
- 26 July 2017
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 59 (1) , 89-92
Abstract
The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after 68Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P < 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: 68Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive 68Ga-PSMA scan results, and higher PSA levels.Keywords
This publication has 14 references indexed in Scilit:
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2017
- Clinical impact of 68 Ga‐prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate‐specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approachBJU International, 2016
- Integration of 68Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective studyRadiation Oncology, 2016
- Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologistsRadiation Oncology, 2015
- 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted TherapyJournal of Nuclear Medicine, 2015
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate CancerPharmaceuticals, 2014
- Prostate Cancer Nomograms: A Review of Their Use in Cancer Detection and TreatmentCurrent Urology Reports, 2014
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2014